Tab%2525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective 5-HT1B/1D receptor agonist used for the acute treatment of migraine. It works by causing cranial vessel constriction and inhibiting the release of pro-inflammatory neuropeptides. It is available as a conventional tablet and an orally disintegrating tablet (ODT). ## Primary Indications * Acute treatment of migraine with or without aura in adults and pediatric patients. ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg. * **Dosing Interval:** If migraine persists or returns, a second dose may be taken at least 2 hours after the initial dose. * **Maximum Dose:** 30 mg in a 24-hour period. ## Pediatric Dosing * **Age 6 to 11 years:** Weight <40 kg: 5 mg; Weight ≥40 kg: 10 mg. * **Age 12 to 17 years:** 10 mg. * **Dosing Interval (All ages):** Maximum of one dose per 24 hours. Efficacy of a second dose has not been established in pediatric populations. ## Dose Adjustments * **Propranolol Users:** Dosage must be reduced to 5 mg (maximum 15 mg in 24 hours) due to increased rizatriptan plasma concentrations. * **Renal/Hepatic Impairment:** No specific dosage adjustment required; use with caution in severe hepatic impairment. ## Contraindications * History of ischemic heart disease (angina, myocardial infarction, silent ischemia). * Coronary artery vasospasm (Prinzmetal’s angina). * Wolff-Parkinson-White syndrome or arrhythmias associated with accessory conduction pathways. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease. * Ischemic bowel disease. * Uncontrolled hypertension. * Administration within 24 hours of another 5-HT1 agonist or ergot-type medication. * Administration within 2 weeks of MAO inhibitors. ## Adverse Effects * **Common:** Paresthesia, dizziness, somnolence, fatigue, and dry mouth. * **Serious:** Coronary artery vasospasm, transient myocardial ischemia, arrhythmias, myocardial infarction, and serotonin syndrome (especially when used with SSRIs/SNRIs). ## Key Drug Interactions * **MAO Inhibitors:** Risk of severe toxicity; contraindicated. * **Propranolol:** Increases rizatriptan bioavailability. * **SSRIs/SNRIs/Triptans:** Potential risk of serotonin syndrome; monitor for symptoms (agitation, tachycardia, hyperreflexia). * **Ergot alkaloids:** Additive vasoconstrictive effects; avoid co-administration within 24 hours. ## Monitoring * Monitor cardiovascular status in patients with multiple risk factors (postmenopausal women, men >40, diabetics) upon first dose. * Assess for evidence of medication overuse headache (MOH) if used >10 days per month. * Monitor for signs of serotonin syndrome. ## Clinical Pearls * ODT formulation does not require water; the blister pack should be dry before handling. * Rizatriptan is not indicated for prophylactic treatment of migraine or for cluster headaches. * Advise patients that "triptan sensations" (neck/chest pressure, heaviness) are common but should be reported if severe or persistent. * Cardiovascular evaluation is recommended before clinical use in patients with risk factors for coronary artery disease. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult the most recent FDA-approved prescribing information or institutional clinical protocols before prescribing or administering medication. Clinical practice may vary based on regional guidelines and individual patient factors.